Brief: Aclaris Therapeutics To Discontinue Further Development Of ATI-450 Program

Aclaris Therapeutics

13/11/2023 12:02

Nov 13 (Reuters) - Aclaris Therapeutics Inc  ACRS.O :
    * ACLARIS THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM 12-WEEK PHASE 2B
TRIAL OF
ORAL ZUNSEMETINIB (ATI-450) FOR MODERATE TO SEVERE RHEUMATOID ARTHRITIS AND
PROVIDES CORPORATE UPDATE
    * EFFICACY RESULTS DO NOT SUPPORT FURTHER DEVELOPMENT OF ZUNSEMETINIB
    * STUDY DID NOT MEET PRIMARY OR SECONDARY EFFICACY ENDPOINTS IN RHEUMATOID
ARTHRITIS
    * ACLARIS WILL DISCONTINUE FURTHER DEVELOPMENT OF ATI-450 PROGRAM 
    * AS OF SEPTEMBER 30, 2023, ACLARIS HAD AGGREGATE CASH, CASH EQUIVALENTS AND
MARKETABLE SECURITIES OF $187.0 MLN
    * WILL HALT ENROLLMENT OF ACLARIS' ONGOING PHASE 2A TRIAL OF ZUNSEMETINIB IN
PSORIATIC ARTHRITIS 

Source text for Eikon:  ID:nGNXyghML 
Further company coverage:  ACRS.O 

 ((Reuters.Briefs@thomsonreuters.com;;))